Anastasios Konidaris compensation by year
Amneal Pharmaceuticals Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $427,308 | $550,000 | $550,000 | $563,327 | $580,731 | $600,750 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $1,747,367 | $1,770,757 | $1,876,807 | $855,505 | $1,866,575 | $2,249,995 |
| Option awards | $0 | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $327,608 | $326,912 | $289,493 | $453,902 | $386,100 | $423,590 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $6,216 | $16,327 | $16,886 | $18,531 | $18,927 | $19,159 |
| Total | $2,508,499 | $2,663,996 | $2,733,186 | $1,891,266 | $2,852,333 | $3,293,494 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amneal Pharmaceuticals, Inc. DEF 14A filed March 25, 2026, accession 0001308179-26-000143, and prior-year filings.
How this page was built: the Amneal Pharmaceuticals, Inc. filed document, accession 0001308179-26-000143. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 458,719 | $5,779,822 | — |
| PSU | 351,852 | $4,433,335 | — |
| RSU | 131,945 | $1,662,507 | — |
| RSU | 114,679 | $1,444,955 | — |
| RSU | 114,155 | $1,438,353 | — |
| PSU | 114,155 | $1,438,353 | — |
| RSU | 45,290 | $570,654 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Amneal Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Amneal Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,331,803 | $14,745,890 | $58,730 | $16,136,423 |
| Disability | $0 | $9,629,421 | $0 | $9,629,421 |
| Involuntary termination without cause | $1,331,803 | $9,629,421 | $58,730 | $11,019,953 |
| Death | $0 | $9,629,421 | $0 | $9,629,421 |
Per the Potential Payments Upon Termination or Change in Control table in Amneal Pharmaceuticals, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Amneal Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Chintu Patel | Co-Chief Executive Officer and President | $8,730,545 |
| Chirag Patel | Co-Chief Executive Officer and President | $8,691,745 |
| Anastasios Konidaris · this page | EVP & Chief Financial Officer | $3,293,494 |
| Andrew Boyer | EVP, Chief Commercial Officer - Generics | $3,017,163 |
| Jason Daly | EVP, Chief Legal Officer & Secretary | $2,860,442 |
| Nikita Shah | EVP, Chief Human Resources Officer | $2,730,582 |
Anastasios Konidaris's compensation dossier, Amneal Pharmaceuticals
You have read Anastasios Konidaris's totals and holdings. The dossier adds each equity grant Amneal Pharmaceuticals disclosed for Anastasios Konidaris and Amneal Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Amneal Pharmaceuticals compensation record
free company briefThis page is one person within Amneal Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Amneal Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Amneal Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amneal Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.